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S U M M A R Y
Background: The hepatitis B virus (HBV) polymerase gene completely overlapswith the envelope gene. In
the present study we aimed to monitor the prevalence and pattern of the typical mutations for hepatitis
B surface antigen (HBsAg) escape, and concomitantly nucleos(t)ide analog (NUC) resistance mutations,
in Turkish patients undergoing different antiviral therapies and in treatment-naı¨ve patients with chronic
hepatitis B (CHB).
Methods: The investigation was undertaken between March 2007 and August 2009 and involved a total
of 142 patients under NUC therapy (88 males; mean age 42 years (range 13–68); hepatitis B e antigen
(HBeAg) negativity in 94 patients; HBV DNA median log 4.3 log10 IU/ml (range 2.0–>6.0); alanine
aminotransferase (ALT) median level 76.1 IU/ml (range 12–1082)) and 185 treatment-naı¨ve CHB
patients (120 males; mean age 39 years (range 1–76 years); HBeAg negativity in 132 patients; HBV DNA
median log 3.5 log10 IU/ml (range 2.0–6.0); ALT median level 60.7 IU/l (range 8–874)).
Results: The overall prevalence of typical HBsAg escape mutations found in the CHB patients was 8.3%
(27/327). In the NUC therapy group the prevalence was 8.5% (12/142), with the following patterns:
sY100C + sI110V, sL109I, sP120T, sP127T, sG130R + sG145X, sS132A + sY134N, sY134N + sG145R,
sC137G, sD144E, sG145R. In the treatment-naı¨ve group the prevalence was 8.1% (15/185), with the
following patterns: sL109I, sI110V, sS117INST, sP120T, sP127T, sM133I, sC137L + sG145R, sS143L.
However, NUC resistance mutations were found in 7.7% (11/142) of the patients on NUC therapy and
3.8% (7/185) of the treatment-naı¨ve group patients. Interestingly, the treatment-naı¨ve patients had
preexisting drug resistance mutations related to lamivudine (rtL180M + rtM204I), adefovir (rtA181V,
rtQ215S, rtI233V), entecavir (intermediate susceptibility with rtL180M + rtM204IHBV variant),
telbivudine (rtL180M + rtM204I), and tenofovir (rtA194T).
Conclusions: The ﬁndings of this study show preexisting typical HBsAg escape and NUC resistance
mutations are possible. The genetic arrangement of the HBV genome with polymerase and surface genes
overlapping has substantial public health and diagnostic implications and relevance.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The hepatitis B virus (HBV) genome is one of the smallest viral
genomes (approximately 3200 base pairs) and encodes only one
viral enzyme, namely the HBV reverse transcriptase (RT). Like the
HIV RT, the HBV RT is an error-prone enzyme lacking proof-
reading activity. In combination with a high virus production,
this results in HBV quasi-species.1 The use of antiviral agents* Corresponding author. Tel.: +90 0262 3038571; fax: +90 0262 3038085.
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1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.039licensed for the treatment of chronic HBV infection, namely
nucleos(t)ide analogs (NUCs), can lead to the development of
resistance. Additional, compensatory mutations then accumu-
late that help to restore full replicative capacity. It is important to
keep in mind that the HBV polymerase gene completely overlaps
the envelope gene.2 Mutations in and around the major
neutralization domain of HBV, known as the ‘a’ determinant,
may (1) result in HBV reactivation by escape mutants in
previously antibody to hepatitis B surface antigen (anti-HBs)
immune persons, (2) cause diagnostic problems, and (3) result in
failure of infection prevention with vaccination or hepatitis B
immunoglobulin (HBIg).3–5ses. Published by Elsevier Ltd. All rights reserved.
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mutations are sP120T, sM133I, sS143L, sD144A/E, sG145R, sE164D,
sW172*, and sW182*, which is the most common pattern.4,6,7
Vaccine/HBIg escape mutations sG145R and sP120T in combina-
tion with lamivudine (LAM)-associated resistance mutations are
often seen in HBV-mono-infected patients following LAM or HBIg
treatment.8 The mutation selected during NUC resistance can
cause concomitant changes in the overlapping reading frame
with the major resistance mutations for LAM, adefovir (ADV),
and entecavir (ETV), in particular altering the C-terminal region
of HBsAg.9 Studies have shown that LAM-resistant HBV
(rtV173L + rtL180M + rtM204V) has signiﬁcantly reduced anti-
HBs binding due to changes in the HBsAg.2,10 However, the point
mutation that causes the rtA181T change in the polymerase also
encodes a stop codon (sW172*) in surface proteins.11 A recent
report has provided evidence for the involvement of HBV encoding
the rtA181T/sW172* mutation in the pathogenesis of, and
progression to, hepatocellular carcinoma (HCC).12
Turkey is an intermediate endemicity area (2–7%) with
approximately 6500 individuals newly infected with HBV each
year.13–15 A recent study in Turkey found an overall prevalence of
4.19% for HBsAg at 22 Red Crescent Centers between 1989 and
2004,13 but the prevalence rates seen in southeastern Turkey are
highest (9–11%).16 Moreover, many studies have indicated that
Turkish patients with chronic hepatitis B (CHB) show very little
genotypic heterogeneity.17,18 In fact, according to a complete HBV
genome sequence study, most of the HBsAg carriers in Turkey have
a very similar S gene sequence (subtype ayw2).14 However, little is
known about HBsAg escape mutations. An HBV vaccine escape
mutation (sT143stop codon) was recently identiﬁed for the ﬁrst
time in Turkey in a child with CHB.19 A study sequencing the
ampliﬁed surface gene region has suggested sM125T and sT127P
mutations as HBsAg escape mutations in Turkish patients with
CHB and their family members.15 Another recently published
paper described a diagnostic HBsAg escape mutation (sS143L)
causing chronic HBV infection in a previously vaccinated treat-
ment-naı¨ve Turkish patient.20
The aim of the present studywas tomonitor the prevalence and
pattern of the typical HBsAg escape mutations, and concomitantly
drug resistancemutations, in NUC therapy patients and treatment-
naı¨ve patients with CHB in Turkey.
Materials and methods
Patients
The study was carried out between March 2007 and August
2009 at Kocaeli University Hospital and involved those patients
whowere starting NUC therapy and those whowere already under
treatment during this time period. All HBV DNA-positive samples
detected by real-time PCR were included. In three patients with
undetectable serum HBV DNA levels in the real-time PCR,
detection was by an in-house HBV PCR. A total of 327 patients
were included in the study; 142 patients were already undergoing
NUC therapy and 185 were treatment-naı¨ve CHB patients. The
patients in the NUC therapy group were being treated with oral
LAM (Zefﬁx1 100 mg/day, GlaxoSmithKline, Middlesex, UK), ADV
(Hepsera1 10 mg/day, Gilead Sciences, Inc., Foster City, USA), ETV
(Baraclude1 0.5 mg/day and 1 mg/day, Bristol-Myers Squibb Co.,
Princeton, USA), or tenofovir (TDF; Viread1 245 mg/day, Gilead
Sciences, Inc., Foster City, USA) as monotherapy or combination
therapy. All of the patients were categorized as chronic HBV
carriers according to the European Association for the Study of the
Liver (EASL) clinical practice guidelines.21 Liver damage was
determined according to Knodell’s classiﬁcation.22 ‘Add-on’ and
‘switch’ NUC therapy strategies were used in the gastroenterologyand infectious diseases departments. In those patients who were
receiving NUC therapy, the timing of the serum sample collection
was according to virological and/or biochemical breakthrough.
Blood samples were immediately separated by centrifugation, and
the separated sera aliquoted and kept at 20 8C until testing.
Serological markers of HBV (HBsAg, anti-HBs, antibodies to
hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg),
and antibody to hepatitis B e antigen (anti-HBe)) were tested using
commercially available microparticle enzyme immunoassay kits
(Axsym, Abbott Laboratories, IL, USA and Elecsys, Roche Diag-
nostics, Mannheim, Germany). However, serological data showed
that all patients were HBsAg-positive and that hepatitis C virus
(HCV; Axsym, Abbott Laboratories, IL, USA and Elecsys, Roche
Diagnostics, Mannheim, Germany), hepatitis D virus (HDV; Dia.Pro
Diagnostic Bioprobes, Milan, Italy), and HIV (Axsym, Abbott
Laboratories, IL, USA and Elecsys, Roche Diagnostics, Mannheim,
Germany) markers were negative. None of the patients had
received the HBV vaccination before their diagnosis of chronic HBV
carrier. Clinical features of the study patients according to the EASL
clinical practice guidelines are shown in Table 1.
DNA isolation and HBV DNA assay
HBV DNA was isolated from serum samples by a biorobot
workstation using magnetic particle technology (NucliSENS-easy-
MAG, bioMe´rieux, Boxtel, the Netherlands). HBV DNA was
detected and quantiﬁed by a commercial real-time PCR assay
(Iontek Biotechnology Inc., Istanbul, Turkey; iCycler iQ5, BioRad
Laboratories Inc., CA, USA). An HBV nested PCR was also used, as
previously reported by Karatayli et al.23
Sequencing of the HBV polymerase gene region
Brieﬂy, a pair of primers was designed (forward: 50-
TCGTGGTGGACTTCTCTCAATT-30 and reverse: 50- CGTTGACA-
GACTTTCCAATCAAT-30) for the HBV polymerase gene region. The
PCR conditions for the polymerase gene segment were as follows:
95 8C for 15 min, and 45 cycles consisting of 95 8C for 45 s, 56 8C for
45 s, and 72 8C for 45 s. The ﬁnal concentration of primer pairs was
0.3mM. The size of the amplicon in HBV was around 742 bp, and
included all the known NUC resistance mutations in HBV. All PCR
productswerepuriﬁedusingtheHighPurePCRProductsPuriﬁcation
Kit (Roche Diagnostics GmbH, Mannheim, Germany) and directly
sequenced with the ABI PRISM 310 Genetic Analyzer using the
DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Phar-
macia Biotech Inc., Piscataway, USA). For the cycle sequencing the
followingthermalprotocolwasused:35cyclesconsistingof95 8Cfor
20 s,50 8Cfor25 s,andﬁnally60 8Cfor2 min.Thereverseprimerwas
usedas thesequencingprimerataﬁnalconcentrationof0.5mM.The
electropherograms were assembled using Vector NTI v5.1 (Infor-
MaxTM InvitrogenTM Life Science Software, Frederick, MD, USA).
Determination of HBV genotype
HBV genotypes were determined by the genotyping tool of the
National Center for Biotechnology Information (NCBI, US National
Library of Medicine, Bethesda, MD, USA, http://www.ncbi.nih.gov/
projects/genotyping/formpage.cgi), which identiﬁes the genotype
based on the viral nucleotide sequences. The genotyping tool
works by using BLAST to compare a query sequence to a set of
reference sequences for known genotypes.24
Determination of surface and polymerase gene mutations
The genafor/arevir–geno2pheno HBsAg escape/drug resistance
tool (Center of Advanced European Studies and Research, Bonn,
Table 1
Demographic data and clinical features of the study patients
Characteristic Treatment-naı¨ve group Nucleos(t)ide analog therapy group
Patients, na 185 142
Male, n (%) 120 (64.9) 88 (62.0)
Age, median years (range) 39 (1–76) 42 (13–68)
ALT, median U/l (range) 60.7 (8–874) 76.1 (12–1082)
AST, median U/l (range) 54.7 (13–2510) 58 (13–709)
HBV DNA, median log IU/ml (range) 3.5 log10 (2.0–6.0) 4.3 log10 (2.0–>6.0)
HBV genotype (%) A (0.5); D (99.5) D (100)
Patient chronic hepatitis B historyb Patients with new detection, n=38 Patients in the immune tolerant phase, n=25
Patients immune tolerant on follow-up, n=12 Patients in the immune reactive phase, n=23
Patients within waiting period for 6 months, n=3 HBeAg-negative CHB patients, n=94
Patients with new initial antiviral treatment, n=10
Inactive HBV carriers, n=122c
HBeAg-negative CHB patients, n=132
Biopsy status Patients with Knodell ﬁbrosis scores, n=23
(score 1 in 15%, 2 in 60%, 3 in 15%,
4 in 5%, and 7 in 5%)
Patients with Knodell ﬁbrosis scores, n=61
(score 1 in 17%, 2 in 70%, 3 in 10%, and 5 in 3%)
Patients without biopsy, n=162 Patients with planned biopsy/waiting for biopsy, n=32
Patients without biopsy, n=49
Therapy statusd - LAM!ADV (32 patients); LAM!
ADV!ETV
(6 patients); LAM!ADV!ETV!TDF (1 patient);
LAM!ADV!TDF (5 patients); LAM!ETV (14 patients);
LAM!TDF (1 patient);
LAM! LAM+ADV (41 patients); LAM! LAM+ETV (13 patient);
ADV!ETV (18 patients); ADV!ETV!TDF (1 patient);
ADV!ADV+ETV (9 patients);
ETV!ETV+TDF (1 patient)
Treatment duration, median months (range) - LAM: 27.9 (2–126); LAM+ADV: 25 (8–50); ADV: 16.2 (1–38);
ADV+ETV: 18 (8–24); ETV: 13.4 (8–26); ETV+TDF: 6 months
(only 1 patient); TDF: 4.2 (3–5)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; CHB, chronic hepatitis B; LAM, lamivudine; ADV,
adefovir; ETV, entecavir; TDF, tenofovir.
a Serological markers of all patients were found negative for hepatitis C virus and hepatitis D virus.
b Patient history is recorded as per the European Association for the Study of the Liver clinical practice guidelines.21.
c Three patients had undetectable serum HBV DNA levels on quantitative HBV real-time PCR; detection was by in-house HBV PCR.
d ‘Switch’ or ‘add-on’ therapywas decided according to the emergence of drug-resistance (primary or compensatory resistance) or clinical and/or virological breakthrough.
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database that has been speciﬁcally designed for rapid computer-
assisted virtual phenotyping of HBV, and accepts genome (nucleic
acid) sequences as input. Geno2pheno searches for homology
between input sequences and others already stored in its database,
which also stores relevant clinical data for drug resistance and
surface genemutations. The data accumulated by direct sequencing
were analyzed either manually or using the geno2pheno tool. The
geno2pheno tool searches for HBV drug resistance mutations in the
RT domain of the polymerase gene at amino acid positions 80, 169,
173, 180, 181, 184, 194, 202, 204, 215, 233, 236, and 250. However,
additional RT amino acid substitutions at positions 84, 85, 214, 237,
and238were searched formanually.25 Theoverlapping surface gene
segmentwas searchedby thegeno2phenotool,mostly forﬁveamino
acid substitutions at positions 137, 141, 144, 145, and 147.
Additionally, this regionwas also searched formutations at positions
100, 109, 110, and 112–157 manually.7 An interpretation of the RT
aminoacid substitutionswas performedﬁrstmanually and secondly
by geno2pheno tool database in the same nucleic acid sequence.
Statistical analysis
The signiﬁcance of differences between two proportions was
determined by Chi-square test with Yates’ correction for continuity.
Results
Fifteen typical HBsAg escape mutations were detected in the
patients: sY100C, sL109I, sI110V, sS117INST, sP120T, sP127T,
sG130R, sS132A, sM133I, sY134N, sC137L, sC137G, sD144E,
sG145X, and sG145R (Table 2). The prevalence of typical HBsAg
escape mutations found in all CHB patients was 8.3% (27/327). Thefrequency of these mutations in the NUC therapy group was 8.5%
(12/142) and in the treatment-naı¨ve group was 8.1% (15/185). The
difference in frequency of HBsAg escape mutations was not
signiﬁcantly different between the groups; Chi-square with Yates’
correction = 0.07; p > 0.05 (0.7). In the NUC therapy group, ten
different patterns of the typical HBsAg escape mutations were
found: sY100C + sI110V, sL109I, sP120T, sP127T, sG130R + sG145X,
sS132A + sY134N, sY134N + sG145R, sC137G, sD144E, sG145R; in
the treatment-naı¨ve group patients, eight different patterns were
found: sL109I, sI110 V, sS117INST, sP120T, sP127T, sM133I, sC137L
+ sG145R, sS143L. Someof the typicalHBsAg escapemutationswere
immune-selected: sP120T, sM133I, sD144E, sS143L, and sG145R,
detected in 10 patients. Three of these patients were treatment-
naı¨ve and developed LAM + telbivudine (LdT), ADV, and TDF drug
resistance; seven patients were in the NUC therapy group and three
of these developed LAM, LAM + LdT, and ADV drug resistance,
respectively (Table 2).However, theprevalenceof themost reported
vaccine escapemutation, sG145R,was found tobe1.2% (4/327) in all
the CHB patients.
LAM, LdT, ADV, ETV, and TDF drug resistance mutations were
detected in the CHB patients: rtL180 M + rtM204I/V, rtM204I,
rtA181V/T, rtQ215S, rtI233V, rtN236T, rtL180M + rtS202C +
rtM204V, and rtA194T/V. Additionally, in some patients, drug
resistance mutations were detected with compensatory mutations:
rtL80F, rtL180 V, rtA194G, rtV214P, rtQ215H/P, rtI233S, rtN236S,
and rtM250R (Table 2). In the treatment-naı¨ve patients with
preexisting drug resistance mutations, these were related to LAM
(rtL180M + rtM204I), ADV (rtA181V, rtQ215S, rtI233V), ETV (inter-
mediate susceptibility with rtL180M + rtM204I HBV variant), LdT
(rtL180M + rtM204I), and TDF (rtA194T) (Table 2). However, NUC
resistancemutationswere found in7.7%(11/142) in theNUCtherapy
group and 3.8% (7/185) in the treatment-naı¨ve group. This distinct
Table 2
Characteristics of HBsAg escape mutation-positive subjects and concomitant nucleos(t)ide analog resistance mutations
Patient Gender,
age (years)
Treatment status Typical HBsAg
escape mutation
Nucleos(t)ide analog
resistance mutation
Compensatory
mutation
Drug resistance
1 Male, 52 Treatment-naı¨ve sL109I rtA181Va - LAM, ADV
2 Female, 36 Treatment-naı¨ve sI110V - - -
3 Female, 64 Treatment-naı¨ve sI110V - - -
4 Female, 54 Treatment-naı¨ve sI110V rtA194V, rtQ215H -
5 Female, 44 Treatment-naı¨ve sS117INST - -
6 Female, 25 Treatment-naı¨ve sP120T rtL180M+rtM204Ia - LAM, LdT
7 Male, 76 Treatment-naı¨ve sP127T rtQ215S - ADV
8 Female, 52 Treatment-naı¨ve sP127T - - -
9 Female, 36 Treatment-naı¨ve sP127T - - -
10 Male, 55 Treatment-naı¨ve sP127Tb rtI233Vb - ADV
11 Male, 48 Treatment-naı¨ve sP127T - - -
12 Female, 29 Treatment-naı¨ve sM133I - rtI233S, rtM250R -
13 Female, 62 Treatment-naı¨ve sL109I rtM204I - LAM, LdT
14 Male, 56 Treatment-naı¨ve sS143L rtQ215S rtA194G ADV
15 Male, 26 Treatment-naı¨ve sC137L+ sG145R rtA194T - TDF
16 Male, 55 LAM, 36 months sY100C+sI110Vb rtA181Tb,c - LAM, ADV
17 Male, 53 LAM, 6 months sL109I rtA181V - LAM, ADV
18 Male, 35 LAM, 18 months sP120T rtL180M+rtM204Ia - LAM, LdT
19 Female, 38 ETV, 3 months sP127Tb rtM204Ib - LAM, LdT
20 Male, 32 LAM, 36 months sS132A+ sY134N rtL180M+rtS202C+ rtM204V rtV214P ETV
21 Male, 44 ADV, 48 months sY134N+sG145R rtI233V rtN236S ADV
ADV+LAM, 12 months
22 Female, 32 LAM, 36 months sG130R+ sG145X rtA181V - LAM, ADV
ADV, 24 months
23 Female, 41 ADV, 12 months sC137G rtL180M+rtM204I, rtI233S rtL180V LAM, LdT, ADV
24 Male, 53 LAM, 24 months sD144E rtL180M+rtM204V rtL80F LAM
25 Male, 14 LAM, 24 months sD144E rtQ215S rtQ215P ADV
26 Male, 42 ADV, 48 months sG145R rtN236Tc - ADV
ADV+LAM, 12 months
27 Male, 76 LAM, 1 month sG145R - - -
HBsAg, hepatitis B surface antigen; LAM, lamivudine; ADV, adefovir; LdT, telbivudine; TDF, tenofovir; ETV, entecavir; HBV, hepatitis B virus.
a According to the European Association for the Study of the Liver clinical practice guidelines 2009, rtA181V-positive and rtL180M + rtM204I-positive HBV variants are
intermediately susceptible to LAM and ETV, respectively.
b HBsAg escape and nucleos(t)ide analog resistance mutations detected after in-house HBV PCR in patients 10, 16, and 19.
c Mutations only detected manually: rtA181T in patient 16 and rtN236T in patient 26.
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square with Yates’ correction = 3.37; p> 0.05 (0.066).
The NUC therapy and treatment-naı¨ve group patients had
respective values of HBV viral loadmedian 4.3 log10 (2.0–>6.0) and
3.5 log10 (2.0–6.0), alanine aminotransferase (ALT) median 76.1
(12–1082) U/l and 60.7 (8–874) U/l, and aspartate aminotransfer-
ase (AST) median 58 (13–709) U/l and 54.7 (13–2510) U/l; these
values were not found to be related to HBsAg escape and NUC
resistance mutations. However, the medians of these baseline
characteristics in the two groups were found to be signiﬁcantly
different according to the Mann–Whitney U-test (HBV viral load
median z score = 4.314, p = 0.000; ALT median z score = 2.562,
p = 0.010), with the exception of median AST (z score = 1.470,
p = 0.141). In addition, patient age and gender were not correlates
with the presence of detected mutations.
Knodell’s ﬁbrosis scores of the NUC therapy and treatment-
naı¨ve group patients were not correlated between the two groups
or with the presence of detected mutations.
Direct sequencing results revealed HBV genotype D in all
patients, except for one patient with genotype A – an inactive HBV
carrier in the treatment-naı¨ve group (Table 2).
Discussion
The typical HBsAg escape mutations detected in this study
(sP120T, sG130R, sM133I, sY134N, sD144E, sS143L and sG145R)
have been shown in many investigations to cause diagnostic
problems in HBsAg assays and vaccine or HBIg therapy
escape.5,7,26,27 However, insufﬁcient data are available for inter-
pretation, and the clinical effects of some of the detected typical
HBsAg escape mutations found in this study (i.e., sY100C, sL109I,
sI110V, sS117INST, sP127T, sS132A, sC137L, sC137G, sG145X) arenot clear in the background literature.7 Fifteen typical HBsAg
escape mutations were detected in our study patients, and these
were single or multiple. To date, Turkish data have been limited to
case studies and this is the ﬁrst report of HBsAg escape mutations
in Turkish CHB patients. In most geographical regions, the
prevalence of these mutants in the population of HBV carriers is
unknown. By DNA sequence analysis, a frequency close to 33% has
been found in Korean carriers, 38% in Gambian carriers, and 40% in
Spanish carriers. sP120T, sL127P, sG129H, sM133I/T, sP/T134A/L,
sS140L, and sG145A/R were the most frequent HBsAg escape
mutations representing the ‘a’ determinant of the polymerase
protein of HBV in these studies.7,28 The frequency of typical HBsAg
escape mutations according to polymerase gene sequencing of
HBV found in our study is lower than that found in other
studies.7,28 This higher detected frequency in the other studies
could be as a result of using the DNA sequencing method to focus
on all amino acid substitutions in the surface gene of HBV. On the
other hand, clonal analysis may have been used in these studies
and this approach can provide more information, especially
whether the mutation is on the same genome. Recently, the ﬁrst
vaccine escape mutation (sT143*) was identiﬁed in Turkey,
concomitantly with other HBsAg escape mutations (sG145A,
sP142S), in a child with CHB who had been vaccinated against
HBV.19 The study of Sayiner et al. showed ﬁve amino acid
mutations (sS143L, sQ101H, sS117N, sT118R, sP120Q) in a
treatment-naı¨ve and previously vaccinated Turkish patient.20
However, in our previous study, we demonstrated naturally
occurring RT sequence changes related to NUCs in treatment-
naı¨ve Turkish patients with CHB.29 There has been no information
in Turkey on the prevalence and pattern of typical HBsAg escape
mutations and concomitant NUC resistance mutations in different
antiviral therapies and in treatment-naı¨ve patients with CHB.
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the characteristics of the HBV genome. The major causes of drug
resistance include viral factors, such as the kinetics of viral
production and clearance, and the lack of a proofreading
mechanism during reverse transcription, which creates a large
HBV quasi-species pool and replication ﬁtness of the viral quasi-
species.30 The prevalence of typical HBsAg escapemutations in our
treatment-naı¨ve patients was 8.1% and the patterns were sL109I,
sI110V, sS117INST, sP120T, sP127T, sM133I, sC137L + sG145R, and
sS143L. Interestingly, preexisting drug resistance mutations were
related to LAM (rtL180M + rtM204I, intermediate susceptibility
with rtA181 V HBV variant), ADV (rtA181V, rtQ215S, rtI233V), ETV
(intermediate susceptibility with rtL180M + rtM204I HBV variant),
TDF (rtA194T), and LdT (rtL180M + rtM204I) in a few patients who
were candidates for treatment of their CHB according to current
EASL guidelines.21 These data suggest that the circulation of HBV
encoding surface mutations with concomitant NUC-associated
resistance variants is possible in Turkey. This is particularly the
case for the populations with the highest prevalence rates, in
southeastern Turkey. However, evidence for the spread or
transmission of NUC-resistant HBV is limited.9 In addition, HBV
encoding LAM-resistant mutations has also been found in a cohort
of dialysis patients with occult HBV.31 On the other hand, Ozaslan
et al. reported a high secondary mutation rate for the HBV surface
gene in family members of HBV patients in Turkey.15 Therefore,
monitoring is important in order to determine whether or not
variants can be transmitted and whether they represent an
important public health threat.
The concern is that vaccine escape variants may enhance
resistance to NUCs such as LAM and ADV, and that NUC-resistant
viruses may also, coincidently, be vaccine escape variants.32
A triple mutation pattern related to LAM resistance
(rtV173L + rtL180 M + rtM204 V) has been shown to cause two
amino acid changes in the overlapping surface gene (sE164D +
sI195M), which reduce anti-HBs binding to levels seen only with
the vaccine escape mutant sG145R.33,34 Selection of an sP120A
mutation in these patients is associated with apparent HBsAg
seroconversion. This mutation produces a reduced anti-HBs
binding, which explains the failure to detect HBsAg.5,35 Some of
the typical HBsAg escape mutations have been described as
immune-selectedmutations: s120T, sM133I, sS143L, sD144E, and
sG145R.5 In this study, these were detected in 10 patients and
were predominant in the NUC therapy group. According to our
knowledge, the sS143L mutation was the third mutation
identiﬁed in Turkey, and was detected by HBsAg assays used in
routine laboratories. However, all detected immune-selected
mutations appeared alone. Someof thesepatients developed LAM,
LAM + LdT, and ADV drug resistance (Table 2). According to
recently published studies, envelope changes can be detected
with LAM, ADV, ETV, and TDF resistance.9,36 Vaccine/HBIg escape
mutations sP120T and sG145R in combination with drug
resistance mutations related to LAM are often seen in HBV-
mono-infected patients following LAM or HBIg treatment.8 They
produce changes, rtT128N and rtW153Q, respectively, in the
polymerase gene and have been found to partially restore the in
vitro replicative capacity of LAM-resistant HBV.5,33 At the same
time, the sM133I immune-selected mutation induces changes in
the rtV142I mutation in the overlapping polymerase gene.
However, there are insufﬁcient data available for interpretation
of themutation rtV142I. The choiceof ﬁrst treatment strategymay
affect the efﬁcacy of future treatment options.37 Therefore, NUC
resistance mutations should not be selected by HBV encoding
envelope mutations, particularly surface mutations, and vice
versa, for the effective treatment of CHB.
In this study the rtA194T drug resistance mutation was
detected as a preexisting mutation, and the rtN236T drugresistance mutation was detected in those under NUC therapy.
Neither the ADV-associated resistance mutation rtN236T nor the
TDF-associated resistance mutation rtA194T causes changes in the
HBV surface gene.9,38,39 Interestingly, the sG145R escape mutation
was detected in both groups of patients (Table 2). Therefore, it is
possible to say that the sG145R escape mutation occurred
naturally in these patients. According to our results, the sG145R
escapemutation prevalencewas detected at a low frequency (1.2%)
in Turkish patients with CHB. Amino acid changes in residue 145
have been found at a low frequency (0.4%, 1/272) in HBV carriers in
Spain.7 Naturally occurringmutants of the residue 145 are difﬁcult
to obtain, but are required in HBsAg seroconversionmutant panels.
Manufacturers of commercially available seroconversion panels
are enhancing the ability of the assays to detect HBs mutants in
sufﬁcient amounts to allow for comparisons with different HBsAg
assays on the market.26,40 The variant sG145R was identiﬁed
initially as a vaccine escape mutant.27 It has been demonstrated
that it is also associated with HBV-related chronic liver disease in
non-vaccinated subjects.27,41 On the other hand, the horizontal
transmission of the sG145Rmutant strain has been reported.42 The
patients in this study with sG145R mutant strains had never been
vaccinated and had not received HBIg prior to the development of
their HBV infection. However, naturally occurring surface gene
variants have also been reported around the world in persons who
have not been immunized.43,44
The replication defects in HBV can partially be compensated by
selection according to secondary (compensatory) mutations.4
Some of these compensatory mutations (rtL80F, rtV214P,
rtQ215H/P, rtI233S, rtN236S) were detected in this study, usually
in patients under LAM and/or ADV therapy, and most of these are
associated with ADV failure.25 According to our previous study,
such compensatory mutations can occur in treatment-naı¨ve
patients.29 Furthermore, variations at rtQ215 have been detected
relatively frequently, affecting treatment-naı¨ve and LAM-pre-
treated patients.45 In particular, the rtQ215H substitution has also
been observed in patients receiving LAM or ADV therapy, but its
virological and clinical relevance remain unclear.46 In this study,
no close relationship between compensatory mutations and HBV
viral loads was found. Viral load may be an indirect marker of
replication efﬁciency. Nevertheless, detailed evaluation of the
replication capacity was not one of the aims of this study.
In a recent study, it was demonstrated that mutations in the
HBsAg selected by LAM therapy developedmore frequently in HBV
genotype A when compared with genotype D.36 Several studies
have shown genotype D of HBV to represent almost the whole
Turkish patient population infected with HBV.14,17,29,47 The
present study showed that genotype D of HBV is still dominant
among Turkish HBV-infected patients; genotype A was found in
only one patientwhowas an inactiveHBV carrier. As our groupwas
genotype D dominant, it was not possible to make a comparison of
mutations related to the different HBV genotypes. However, it
would be worthwhile to see if mutations related to HBsAg escape
occur more frequently in HBV infections of some genotypes than
others.
In this study, an interpretation approach, manual analysis, and
an HBsAg escape/drug resistance tool were used. The results of the
manual and geno2pheno tool analyses were similar except in the
cases of two patients with ADV drug resistance (rtA181T and
rtN236T, in patients 16 and 26, respectively) (Table 2). In the DNA
chromatogram of these patients, two peaks were obtained (wild
and mutant type) for the same nucleotide signal (data not shown).
Due to the algorithm used in the HBsAg escape/drug resistance
tool, the most prominent signal is deﬁned as a nucleotide.
Therefore, one must be careful when using such a tool in order
to avoid inaccuracies. However, manual analysis and the HBsAg
escape/drug resistance tool can be used together for interpretation.
M. Sayan et al. / International Journal of Infectious Diseases 14S (2010) e136–e141 e141On the other hand, the geno2pheno is a useful tool that enables a
simple and rapid analysis for the identiﬁcation of mutations
associated with HBsAg escape and resistance to NUCs in large
regions of the HBV genome sequence, as was done in this study.
In this study we focused on the typical HBsAg escapemutations
via DNA sequencing of the polymerase gene region. By thismethod
it is possible to monitor NUC resistance mutations concomitantly
in the same sequencing. In conclusion, our ﬁndings show
preexisting typical HBsAg escape and NUC resistance mutations
are possible. Drug resistance mutations in the HBV polymerase
gene may not always result in a direct impact on the nature of
HBsAg and its function, and vice versa. However, the genetic
arrangement of the HBV genome with polymerase and surface
genes overlapping has substantial public health and diagnostic
implications and relevance.
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